L'intérêt à découvert pour Corbus Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Corbus Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock, Rapport sur les intérêts à découvert

CORBUS PHARMACEUTICALS HOLDI

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

Mobiquity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBQ#NASDAQ">MOBQ</a>) reported quarterly losses of $(0.12) per share. This is a 50 percent increase over losses of $(0.24) per share from the same period last year. The company reported $12.61 thousand in sales this quarter. This is a 95.21 percent decrease over sales of $263.28 thousand the same period last year.

Earnings

News

MOBQ

Mobiquity Technologies Q1 GAAP EPS $(0.12) Up From $(0.24) YoY, Sales $12.61K Down From $263.28K YoY

VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) reported quarterly losses of $(0.06) per share. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported $246.38 thousand in sales this quarter. This is a 43.64 percent increase over sales of $171.53 thousand the same period last year.

VNRX

VolitionRX Q1 EPS $(0.06) Up From $(0.10) YoY, Sales $246.38K Up From $171.53K YoY

Offerings

LOAR

Loar Holdings Files For Offering Of 9M  Shares Of Common Stock By Selling Stockholders

Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) anticipate consolidated Q2 revenue to remain in line with the Q1 2025

Guidance

FLNT

Fluent anticipate consolidated Q2 revenue to remain in line with the Q1 2025

Highlights
<ul>
<li>Transaction includes approximately 2,600 megawatts of modern natural gas generation assets at an attractive price of approximately $743/kW of capacity.</li>
<li>Acquisition is expected to deliver Ongoing Operations AFCFbG1 accretion in year one following closing.</li>
<li>Reiterating previously communicated capital allocation plan, including long-term net leverage target of less than 3x2, the expected return of capital to shareholders by way of the planned $300 million in annual dividends and at least $1 billion of share repurchases each year.</li>
</ul>
IRVING, Texas, May 15, 2025 /PRNewswire/ -- Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) today announced that it has executed a definitive agreement to acquire seven modern natural gas generation facilities, totaling approximately 2,600 MW of capacity, from Lotus Infrastructure Partners ("Lotus"). The acquisition includes five combined cycle gas turbine facilities and two combustion turbine facilities located across PJM, New England, New York, and California, further geographically diversifying Vistra's natural gas fleet.
 &nbsp;

Vistra To Acquire 2,600 Megawatts Of Modern Natural Gas Assets From Lotus For $743/kW

FIHL

Fidelis Insurance Holdings Files For Mixed Shelf; Size Not Disclosed

WIIM

WKSP

WKSP stock has given up its prior gain. Worksport shares were trading higher following Q1 reported financial results.

Newsmax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) reported quarterly losses of $(0.49) per share. This is a 61.42 percent increase over losses of $(1.27) per share from the same period last year. The company reported $45.30 million in sales this quarter. This is a 11.58 percent increase over sales of $40.60 million the same period last year.

NMAX

Newsmax Q1 EPS $(0.49) Up From $(1.27) YoY, Sales $45.30M Up From $40.60M YoY

Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) reported $765.00 thousand in sales this quarter. This is a 48.17 percent decrease over sales of $1.48 million the same period last year.

WRAP

Wrap Technologies Q1 Sales $765.00K Down From $1.48M YoY

General

Lithium Americas Enters Equity Distribution Agreement With TD Securities; Company May Sell Up To $100M In Common Shares

Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) reported quarterly earnings of $0.51 per share.

MOLN

Molecular Partners Q1 EPS $0.51

Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 125 percent. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $6.74 million which beat the analyst consensus estimate of $6.60 million by 2.16 percent. This is a 103.32 percent increase over sales of $3.31 million the same period last year.

Earnings Beats

Earnings Misses

PPSI

Pioneer Power Solutions Q1 EPS $(0.09) Misses $(0.04) Estimate, Sales $6.74M Beat $6.60M Estimate

Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) reported quarterly losses of $(0.02) per share. This is a 98.32 percent increase over losses of $(1.19) per share from the same period last year. The company reported quarterly sales of $13.81 million which missed the analyst consensus estimate of $15.70 million by 12.01 percent. This is a 26.41 percent decrease over sales of $18.77 million the same period last year.

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

Mawson Infra Gr Q1 EPS $(0.02) Up From $(1.19) YoY, Sales $13.81M Miss $15.70M Estimate

Virgin Galactic Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares are ripping higher in Thursday&#8217;s after-hours session after the company reported better-than-expected financial results <a href="https://www.benzinga.com/pressreleases/25/05/b45451181/virgin-galactic-announces-first-quarter-2025-financial-results-and-provides-business-update">for the first quarter</a>.
Q1 Earnings: Virgin Galactic reported first-quarter revenue of $461,000, beating <a href="http://benzinga.com/quote/SPCE/earnings">estimates</a> of $285,710, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The aerospace and space travel company reported a first-quarter loss of $2.38 per share, beating estimates for a loss of $2.55 per share.
Total revenue was down from $2 million in the prior year&#8217;s quarter due to a pause in commercial spaceflights in an effort to focus on production of its Delta Class SpaceShips. Virgin Galactic said its first spaceflight with the new SpaceShip carrying research payloads is planned for summer 2026. 
The company plans to open future astronaut sales in the first quarter of 2026, with private astronaut spaceflights planned for fall 2026.
Virgin Galactic said it generated&nbsp;$31 million&nbsp;in gross proceeds through the issuance of 6.9 million in an at-the-market offering during the quarter and ended the period with $567 million in cash, cash equivalents and marketable securities.
&#8220;The assets being built as we march through our pre-revenue phase are tremendous, and we expect them to open up a powerful and profitable business model that will benefit from an industry-leading cost structure, fixed-cost leverage as we scale, and an unparalleled customer experience,&#8221; said Michael Colglazier, CEO of Virgin Galactic.
Virgin Galactic guided for second-quarter free cash flow of negative $105 million to negative $115 million, versus negative $122 million in the first quarter. 
Virgin Galactic executives will further discuss the quarter on a conference call set to begin at 5 p.m. ET.
SPCE Price Action: <a href="http://benzinga.com/quote/SPCE">Virgin Galactic shares</a> were up 15.82% after-hours, trading at $3.88 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/contracts/25/05/45434506/rocket-lab-gets-nasa-contract-to-launch-aspera-astrophysics-mission">Rocket Lab Gets NASA Contract To Launch Aspera Astrophysics Mission</a></li>
</ul>
Photo: courtesy of Virgin Galactic.

SPACE

After-Hours Center

Movers

SPCE

Virgin Galactic Stock Rockets Higher On Q1 Earnings Beat

Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) has outperformed the market over the past 5 years by 12.62% on an annualized basis producing an average annual return of 27.74%. Currently, Cenovus Energy has a market capitalization of $24.63 billion. 
Buying $100 In CVE: If an investor had bought $100 of CVE stock 5 years ago, it would be worth $307.21 today based on a price of $13.58 for CVE at the time of writing.
<h3>Cenovus Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747343711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Cenovus Energy 5 Years Ago Would Be Worth Today

Skeena Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SKE#TSX">SKE</a>) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.03) by 1100 percent. This is a 20 percent decrease over losses of $(0.30) per share from the same period last year.

TSX:SKE

Skeena Resources Q1 EPS $(0.36) Misses $(0.03) Estimate

Lithium Americas Files For Mixed Shelf Of Up To $1.0B

XBP Europe Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBP#NASDAQ">XBP</a>) reported quarterly losses of $(0.12) per share. This is a 300 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $37.53 million in sales this quarter. This is a 1.36 percent decrease over sales of $38.05 million the same period last year.

XBP Europe Holdings Q1 EPS $(0.12) Down From $(0.03) YoY, Sales $37.53M Down From $38.05M YoY

Callan Jmb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJMB#NASDAQ">CJMB</a>) reported quarterly losses of $(0.32) per share. This is a 966.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $1.45 million in sales this quarter. This is a 19.05 percent decrease over sales of $1.79 million the same period last year.

CJMB

Callan Jmb Q1 EPS $(0.32) Down From $(0.03) YoY, Sales $1.45M Down From $1.79M YoY

South Bow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOBO#NYSE">SOBO</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.44 by 6.82 percent. This is a 14.55 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $498.00 million which missed the analyst consensus estimate of $527.00 million by 5.50 percent. This is a 8.46 percent decrease over sales of $544.00 million the same period last year.

SOBO

South Bow Q1 Adj. EPS $0.47 Beats $0.44 Estimate, Sales $498.00M Miss $527.00M Estimate

Press Releases

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Health Care

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Comments

Corbus Pharmaceuticals

Intérêt court

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL